ArticleJournal of the American Heart Association2022
Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Associations between lipoproteins and risk of ischemic stroke: a systematic review and meta-analysis of Mendelian randomization studies.Frontiers in neurology · 2025Pooled it
- Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial.BMJ (Clinical research ed.) · 2023Trial
- Lipoprotein(a)-dependent cardiovascular risk in different populations: are thresholds the same?Annals of medicine · 2026Review
- Review
- Lipoprotein (a) and Coronary Atherosclerosis in Intracoronary Imaging - YELLOW II - Lp(a) Study.Cardiovascular drugs and therapy · 2026Article
- Blood Biomarkers and the Risk of Coronary Disease in Atrial Fibrillation.Journal of the American Heart Association · 2026Article
- Association of lipoprotein(a), oxidized phospholipids and apolipoprotein B100 in acute ischemic stroke cohort.Advances in lipoprotein(a) research · 2026Article
- Identifying barriers to lipoprotein(a) testing in secondary cardiovascular prevention and co-designing implementation strategies: an Italian behavior change wheel-informed study.Frontiers in cardiovascular medicine · 2026Article
- Association of Lp(a) With Cardiovascular Disease and All-Cause Mortality in U.S. Hispanics and Latinos.Journal of the American College of Cardiology · 2025Article
- Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study.Journal of atherosclerosis and thrombosis · 2025Article
- Sex Differences in the Association Between Lipoprotein(a) and Cardiovascular Outcomes: The MGB Lp(a) Registry.Journal of the American Heart Association · 2025Article
- Lipoprotein(a) Concentration and Cardiovascular Disease in a Group of Patients With Familial Hypercholesterolemia-A Lipid Clinic Experience.Clinical cardiology · 2025Article
- Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening.American journal of preventive cardiology · 2025Review
- Association of Lipoprotein(a) With Major Adverse Cardiovascular Events Across hs-CRP: A Systematic Review and Meta-Analysis.JACC. Advances · 2024Article
- Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.Lipids in health and disease · 2024Article
- Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.Journal of the American Heart Association · 2024Review
- Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study.Frontiers in endocrinology · 2024Article
- Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States.Journal of the American Heart Association · 2023Observational
- Lipoprotein(a) and the Risk for Recurrent Ischemic Stroke Events.JACC. Advances · 2023Article
- Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.Kidney medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Funding
Abstract
Background It is unclear whether lipoprotein(a) is associated with coronary heart disease (CHD) and ischemic stroke events in White and Black adults with atherosclerotic cardiovascular disease (ASCVD). Methods and Results We conducted a case-cohort analysis, including Black and White REGARDS (Reasons for Geographic and Racial Differences in Stroke) study participants ≥45 years of age with prevalent ASCVD (ie, CHD or stroke) at baseline between 2003 and 2007. Baseline lipoprotein(a) molar concentration was measured in participants with ASCVD who experienced a CHD event by December 2017 (n=1166) or an ischemic stroke by September 2019 (n=492) and in a random subcohort of participants with prevalent ASCVD (n=1948). The hazard ratio (HR) for CHD events per 1 SD (1.5 units) higher log-transformed lipoprotein(a) was 1.26 (95% CI, 1.02-1.56) among Black participants and 1.16 (95% CI, 1.02-1.31) among White participants (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.